JP2007509966A - 複素環化合物およびそれらを製造し使用する方法 - Google Patents
複素環化合物およびそれらを製造し使用する方法 Download PDFInfo
- Publication number
- JP2007509966A JP2007509966A JP2006538290A JP2006538290A JP2007509966A JP 2007509966 A JP2007509966 A JP 2007509966A JP 2006538290 A JP2006538290 A JP 2006538290A JP 2006538290 A JP2006538290 A JP 2006538290A JP 2007509966 A JP2007509966 A JP 2007509966A
- Authority
- JP
- Japan
- Prior art keywords
- group
- halogen
- compound
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC=CCC(NC(*)=C1C(*)=C*)=*(C)C1=* Chemical compound CC=CCC(NC(*)=C1C(*)=C*)=*(C)C1=* 0.000 description 26
- OINZOSLENOWIEH-LQNQUEJISA-N C/C(/c(cc1)ccc1NCCOC1=C(c(cc2)cc(OC)c2OC)Oc2cc(OC)cc(OC)c2C1=O)=C(\C(N1)=O)/SC1=O Chemical compound C/C(/c(cc1)ccc1NCCOC1=C(c(cc2)cc(OC)c2OC)Oc2cc(OC)cc(OC)c2C1=O)=C(\C(N1)=O)/SC1=O OINZOSLENOWIEH-LQNQUEJISA-N 0.000 description 1
- LSEQKOKAYOBTNH-JFLMPSFJSA-N C/C(/c(cc1)ccc1OCCOC1=C(c(cc2)cc(F)c2F)N(C)c(cc(cc2)F)c2C1=O)=C(/C(N1)=O)\SC1=O Chemical compound C/C(/c(cc1)ccc1OCCOC1=C(c(cc2)cc(F)c2F)N(C)c(cc(cc2)F)c2C1=O)=C(/C(N1)=O)\SC1=O LSEQKOKAYOBTNH-JFLMPSFJSA-N 0.000 description 1
- XSFNSTKKMDWDSK-WPWMEQJKSA-N C/C(/c(cc1)ccc1OCCOC1=C(c(cc2)ccc2F)N(C)c(cccc2)c2C1=O)=C(/C(N1)=O)\SC1=O Chemical compound C/C(/c(cc1)ccc1OCCOC1=C(c(cc2)ccc2F)N(C)c(cccc2)c2C1=O)=C(/C(N1)=O)\SC1=O XSFNSTKKMDWDSK-WPWMEQJKSA-N 0.000 description 1
- HJKLCXYGBCGOLI-JVWAILMASA-N C/C(/c(cc1)ccc1OCCOC1=C(c(cc2F)ccc2F)N(C)c(cccc2)c2C1=O)=C(/C(N1)=O)\SC1=O Chemical compound C/C(/c(cc1)ccc1OCCOC1=C(c(cc2F)ccc2F)N(C)c(cccc2)c2C1=O)=C(/C(N1)=O)\SC1=O HJKLCXYGBCGOLI-JVWAILMASA-N 0.000 description 1
- ZLDIFFVIYWTPGV-JVWAILMASA-N C/C(/c(cc1Cl)ccc1OCCOC1=C(c2ccccc2F)N(C)c(cccc2)c2C1=O)=C(/C(N1)=O)\SC1=O Chemical compound C/C(/c(cc1Cl)ccc1OCCOC1=C(c2ccccc2F)N(C)c(cccc2)c2C1=O)=C(/C(N1)=O)\SC1=O ZLDIFFVIYWTPGV-JVWAILMASA-N 0.000 description 1
- YHWGYIHORGPWHS-OGLMXYFKSA-N C/C(/c1cc(OCCOC2=C(c(cc3)cc(F)c3F)N(C)c3ccccc3C2=O)ccc1)=C(/C(N1)=O)\S/C1=[O]\C Chemical compound C/C(/c1cc(OCCOC2=C(c(cc3)cc(F)c3F)N(C)c3ccccc3C2=O)ccc1)=C(/C(N1)=O)\S/C1=[O]\C YHWGYIHORGPWHS-OGLMXYFKSA-N 0.000 description 1
- FELQIHIFAPKOSA-LQNQUEJISA-N C/C(/c1ccccc1OCCOC1=C(c(cc2)cc(OC)c2OC)Oc2cc(OC)cc(OC)c2C1=O)=C(\C(N1)=O)/SC1=O Chemical compound C/C(/c1ccccc1OCCOC1=C(c(cc2)cc(OC)c2OC)Oc2cc(OC)cc(OC)c2C1=O)=C(\C(N1)=O)/SC1=O FELQIHIFAPKOSA-LQNQUEJISA-N 0.000 description 1
- QRVRYBJTVILKOK-UHFFFAOYSA-N CC(c(cc1)ccc1OCCBr)=O Chemical compound CC(c(cc1)ccc1OCCBr)=O QRVRYBJTVILKOK-UHFFFAOYSA-N 0.000 description 1
- QFPMBJXPCXJSSQ-YZSQISJMSA-N CCCc1n[n](C)c2c1NC(C(C1)C=CC(OC)=C1C=O)N(CCOc(cc1)ccc1/C(/C)=C(\C(N1)=O)/SC1=O)C2=O Chemical compound CCCc1n[n](C)c2c1NC(C(C1)C=CC(OC)=C1C=O)N(CCOc(cc1)ccc1/C(/C)=C(\C(N1)=O)/SC1=O)C2=O QFPMBJXPCXJSSQ-YZSQISJMSA-N 0.000 description 1
- YEIAVPUYBFBQHM-ZMFRSBBQSA-N COc(cc1OC(c(cc2OC)ccc2OC)=C2OCCOc(c(OC)cc(/C=C(/C(N3)=O)\SC3=O)c3)c3OC)cc(OC)c1C2=O Chemical compound COc(cc1OC(c(cc2OC)ccc2OC)=C2OCCOc(c(OC)cc(/C=C(/C(N3)=O)\SC3=O)c3)c3OC)cc(OC)c1C2=O YEIAVPUYBFBQHM-ZMFRSBBQSA-N 0.000 description 1
- IIKASBOQALJWKO-UHFFFAOYSA-N Cc(cc1)ccc1C(N(C)c(cccc1)c1C1=O)=C1O Chemical compound Cc(cc1)ccc1C(N(C)c(cccc1)c1C1=O)=C1O IIKASBOQALJWKO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN861CH2003 | 2003-10-28 | ||
US61016304P | 2004-09-15 | 2004-09-15 | |
PCT/US2004/035939 WO2005042712A2 (en) | 2003-10-28 | 2004-10-28 | Heterocyclic compounds and methods of making and using thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007265960A Division JP2008074858A (ja) | 2003-10-28 | 2007-10-11 | 複素環化合物およびそれらを製造し使用する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007509966A true JP2007509966A (ja) | 2007-04-19 |
JP2007509966A5 JP2007509966A5 (no) | 2007-12-13 |
Family
ID=34553826
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006538290A Pending JP2007509966A (ja) | 2003-10-28 | 2004-10-28 | 複素環化合物およびそれらを製造し使用する方法 |
JP2007265960A Pending JP2008074858A (ja) | 2003-10-28 | 2007-10-11 | 複素環化合物およびそれらを製造し使用する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007265960A Pending JP2008074858A (ja) | 2003-10-28 | 2007-10-11 | 複素環化合物およびそれらを製造し使用する方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1678157A4 (no) |
JP (2) | JP2007509966A (no) |
KR (1) | KR20070026306A (no) |
AU (1) | AU2004286277A1 (no) |
CA (1) | CA2540460A1 (no) |
IL (1) | IL174249A0 (no) |
NO (1) | NO20061292L (no) |
RU (1) | RU2006112343A (no) |
WO (1) | WO2005042712A2 (no) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008074858A (ja) * | 2003-10-28 | 2008-04-03 | Reddy Us Therapeutics Inc | 複素環化合物およびそれらを製造し使用する方法 |
JP5670340B2 (ja) * | 2009-09-30 | 2015-02-18 | 株式会社 資生堂 | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 |
CN113507929A (zh) * | 2018-12-21 | 2021-10-15 | 阿科利斯制药有限责任公司 | Dna聚合酶iiic抑制剂及其用途 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006275514B2 (en) | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
KR101444489B1 (ko) | 2007-02-01 | 2014-09-24 | 리스버로직스 코퍼레이션 | 심혈관 질환을 예방 및 치료하기 위한 화합물 |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
PT2421533T (pt) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | Novos agentes anti-inflamatórios |
CZ2009358A3 (cs) * | 2009-06-03 | 2010-12-15 | C3 Bio Gmbh | 5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující |
CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
CN105073744B (zh) | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新型杂环化合物 |
EP3268007B1 (en) | 2015-03-13 | 2022-11-09 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
AU2017246413B2 (en) * | 2016-04-05 | 2021-09-23 | Immune Sensor, Llc | cGAS antagonist compounds |
RU2635112C1 (ru) * | 2016-12-12 | 2017-11-09 | федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" | Галогениды 1-(4-трет-бутилфенил)-2-{ 3-[2-(4-фторфенокси)этил]-2-метил-3Н-бензимидазол-1-ил} этанона, обладающие свойством разрывателей поперечных сшивок гликированных белков |
CN112300141B (zh) * | 2020-10-12 | 2023-04-18 | 贵州大学 | 含喹唑啉的杨梅素衍生物、其制备方法及用途 |
WO2022255765A1 (ko) * | 2021-06-01 | 2022-12-08 | 주식회사 에즈큐리스 | 신규 불소-치환 플라보노이드 유도체 및 이를 포함하는 알러지성 질환의 예방 또는 치료용 약학적 조성물 |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09268189A (ja) * | 1996-01-31 | 1997-10-14 | Ss Pharmaceut Co Ltd | ベンゾアジン誘導体又はその塩及びこれを含有する医薬 |
US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
JP2002515874A (ja) * | 1996-12-31 | 2002-05-28 | ドクター・レディーズ・リサーチ・ファウンデーション | 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用 |
JP2008074858A (ja) * | 2003-10-28 | 2008-04-03 | Reddy Us Therapeutics Inc | 複素環化合物およびそれらを製造し使用する方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0739203A4 (en) * | 1994-01-14 | 2000-12-20 | Cell Therapeutics Inc | METHOD OF TREATING CELL PROLIFERATION CONDITIONS IN RESPONSE TO PDGF, EGF, FGF AND VEGF |
TW399051B (en) * | 1996-01-31 | 2000-07-21 | Ssp Co Ltd | A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose |
CZ298812B6 (cs) * | 1996-07-01 | 2008-02-13 | Dr. Reddy's Laboratories Limited | Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí |
US5885997A (en) * | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
EP0903343B1 (en) * | 1997-09-19 | 2003-05-28 | SSP Co., Ltd. | Alpha-Substituted phenylpropionic acid derivative and medicine containing the same |
US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
-
2004
- 2004-10-28 AU AU2004286277A patent/AU2004286277A1/en not_active Abandoned
- 2004-10-28 RU RU2006112343/04A patent/RU2006112343A/ru not_active Application Discontinuation
- 2004-10-28 EP EP04817481A patent/EP1678157A4/en not_active Withdrawn
- 2004-10-28 JP JP2006538290A patent/JP2007509966A/ja active Pending
- 2004-10-28 KR KR1020067005607A patent/KR20070026306A/ko not_active Application Discontinuation
- 2004-10-28 CA CA002540460A patent/CA2540460A1/en not_active Abandoned
- 2004-10-28 WO PCT/US2004/035939 patent/WO2005042712A2/en active Application Filing
-
2006
- 2006-03-12 IL IL174249A patent/IL174249A0/en unknown
- 2006-03-21 NO NO20061292A patent/NO20061292L/no not_active Application Discontinuation
-
2007
- 2007-10-11 JP JP2007265960A patent/JP2008074858A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09268189A (ja) * | 1996-01-31 | 1997-10-14 | Ss Pharmaceut Co Ltd | ベンゾアジン誘導体又はその塩及びこれを含有する医薬 |
JP2002515874A (ja) * | 1996-12-31 | 2002-05-28 | ドクター・レディーズ・リサーチ・ファウンデーション | 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用 |
US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
JP2008074858A (ja) * | 2003-10-28 | 2008-04-03 | Reddy Us Therapeutics Inc | 複素環化合物およびそれらを製造し使用する方法 |
Non-Patent Citations (4)
Title |
---|
JPN6011004049, Molecules, 2000, Vol.5, P.167−178 * |
JPN6011004050, UKRAINSKII KHIMICHESKII ZHURNAL, 1981, Vol.47,No.1, P.85−87 * |
JPN6011004051, SYNTHESIS, 1977, Vol.2, P.133−135 * |
JPN6011004053, J. Heterocyclic Chem., 1995, Vol.32, P.1019−1025 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008074858A (ja) * | 2003-10-28 | 2008-04-03 | Reddy Us Therapeutics Inc | 複素環化合物およびそれらを製造し使用する方法 |
JP5670340B2 (ja) * | 2009-09-30 | 2015-02-18 | 株式会社 資生堂 | ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物 |
US9101564B2 (en) | 2009-09-30 | 2015-08-11 | Shiseido Company, Ltd. | Heparanase activity inhibitor, wrinkle improving agent containing same, and pharmaceutical composition |
CN113507929A (zh) * | 2018-12-21 | 2021-10-15 | 阿科利斯制药有限责任公司 | Dna聚合酶iiic抑制剂及其用途 |
JP2022515775A (ja) * | 2018-12-21 | 2022-02-22 | アクルクス ファーマシューティカルズ エルエルシー | Dnaポリメラーゼiiic阻害剤及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
NO20061292L (no) | 2006-07-28 |
AU2004286277A1 (en) | 2005-05-12 |
EP1678157A4 (en) | 2009-03-18 |
CA2540460A1 (en) | 2005-05-12 |
JP2008074858A (ja) | 2008-04-03 |
EP1678157A2 (en) | 2006-07-12 |
RU2006112343A (ru) | 2007-12-10 |
IL174249A0 (en) | 2006-08-01 |
WO2005042712A3 (en) | 2005-07-21 |
KR20070026306A (ko) | 2007-03-08 |
WO2005042712A2 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008074858A (ja) | 複素環化合物およびそれらを製造し使用する方法 | |
WO2005040163A1 (en) | Heterocyclic compounds that block the effects of advanced glycation end products (age) | |
TWI549947B (zh) | 治療化合物及組成物 | |
US7335770B2 (en) | Triazine compounds and their analogs, compositions, and methods | |
US7169784B2 (en) | Medical devices employing triazine compounds and compositions thereof | |
US7332489B2 (en) | Methods and compositions of novel triazine compounds | |
US7238692B2 (en) | Medical devices employing triazine compounds and compositions thereof | |
US9676758B2 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto | |
US20050113341A1 (en) | Medical devices employing triazine compounds and compositions thereof | |
US7335656B2 (en) | Medical devices employing triazine compounds and compositions thereof | |
MXPA01005628A (es) | Compuestos heterociclicos aromaticos como agentes antiinflamatorios. | |
BR112021014977A2 (pt) | Derivados de acetamido como inibidores de dna polimerase teta | |
EA009728B1 (ru) | Триазиновые соединения и их применение в медицине | |
MXPA06003198A (en) | Heterocyclic compounds and methods of making and using thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071011 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071011 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110714 |